Advertisement

Immunocytochemical Studies of Substance P and Met-Enkephalin in the Globus Pallidus of Progressive Supranuclear Palsy

  • Sadayuki Matsumoto
  • Satoshi Goto
  • Hidehiro Mizusawa
  • Asao Hirano
Part of the Advances in Behavioral Biology book series (ABBI, volume 38A)

Abstract

The globus pallidus (GP) is considered to receive the afferent nerve fibers originating mainly from the striatum1 and may play a role in expression of the striatal functions. 2 Substance P(SP) and Met-enkephalin (MEnk) are neuropeptides that have been demonstrated in the basal ganglia and appear to be part of the straitopallidal and striatonigral projections.3 4 A study on the regional distribution of the peptides in the GP showed the internal segment to be rich in SP and an abundance of MEnk in the external segment.3 Based on neurochemical measurements and on immunohistochemical studies, abnormalities in basal ganglia SP and MEnk have been reported in Huntington’s disease (HD)4–7 and Parkinson’s disease (PD).6–8 Progressive supranuclear palsy (PSP), a parkinsonian-like syndrome, is characterized by supranuclear ophthalmoplegia, axial dystonia, and pseudobulbar palsy.9 Histologically, neuronal cell loss, gliosis, and neurofibrillary tangles involve mainly the globus pallidus, subthalamic nucleus, substantia nigra, and other brainstem tegmental nuclei. Few reports have appeared on SP and MEnk in the basal ganglia of PSP. In one study no significant alterations were observed,10 and one case report showed some decrease in SP content in the external segment of the pallidum.11 To ascertain whether some alteration is present in the striatal efferent nerve terminals, we performed an immunohistochemical study on the globus pallidus of PSP patients.

Keywords

Progressive Supranuclear Palsy Globus Pallidus Progressive Supranuclear Palsy Progressive Supranuclear Palsy Patient Internal Segment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    C. A. Fox, and J. A. Rafols, The radial fibers in the globus pallidus, J. Comp. Neurol. 159: 177 (1975).PubMedCrossRefGoogle Scholar
  2. 2.
    J. M. Deniau, and G. Chevalier, Synaptic organization of the basal ganglia: an electroanatomical approach in the cat, in: “Functions of the Basal Ganglia, Ciba Foundation Symposium 107, ” D. Evered and M. O’Conner, eds., Pitman, London (1984).Google Scholar
  3. 3.
    I. Kanazawa, P. C. Emson, and A. C. Cuello, Evidence for the existence of Substance P-containing fibers in striato-nigral and pallidonigral pathways in rat brain, Brain Res. 119: 447 (1977).PubMedCrossRefGoogle Scholar
  4. 4.
    P. C. Emson, A. Arregui, V. Clement-Jones, B. E. B. Sandberg, and M. Rossor, Regional distribution of methionine-enkephalin and Substance P-like immunoreactivity in normal human brain and in Huntington’s disease, Brain Res. 199: 147 (1980).PubMedCrossRefGoogle Scholar
  5. 5.
    I. Kanazawa, E. Bird, R. O’Connell, and D. Powell, Evidence for a decrease in substance P content of substantia nigra in Huntington’s chorea, Brain Res. 120: 387 (1977).PubMedCrossRefGoogle Scholar
  6. 6.
    J. Constantinidis, C. Bouras, and J. Richard, Putative peptide neurotransmitters in human neuropathology: a review of topography and clinical implications, Clin. Neuropathol 2: 47 (1983).PubMedGoogle Scholar
  7. 7.
    M. R. Grafe, L. S. Forno, and L. F. Eng, Immunocytochemical studies of substance P and met-enkephalin in the basal ganglia and substantia nigra in Huntington’s, Parkinson’s and Alzheimer’s diseases, J. Neuropathol. Exp. Neurol. 44: 47 (1985).PubMedCrossRefGoogle Scholar
  8. 8.
    U. K. Rinne, J. 0. Rinne, J. K. Rinne, K. Laakso, and P. Lonnberg, Brain neurotransmitters and neuropeptides in Parkinson’s disease, Acta Physiol. Pharmacol. Latinoam 34: 28 (1984).Google Scholar
  9. 9.
    J. C. Steele, J. C. Richardson, and J. Olszewski, Progressive supra-nuclear palsy: heterogeneous degeneration involving the brainstem, basal ganglia and cerebellum, with vertical gaze and pseudobulbar palsy nuclear dystonia and dementia, Arch. Neurol 10: 33 (1964).CrossRefGoogle Scholar
  10. 10.
    H. Taquet H, F. Javoy-Agid, A. Mauborgne A, J. J. Benoliel, Y. Agid, J. C. Legrand, M. Hauron, and F. Cesselin, Brain neuropeptides in progressive supranuclear palsy, Brain Res. 411: 178 (1987).PubMedCrossRefGoogle Scholar
  11. 11.
    K. Fujiyoshi, H. Suga, H. Nagata H, S. Nakamura, M. Kameyama, Changes of neuropeptides in the patient with progressive supranuclear palsy, Clin. Neurol. (Tokyo) 24: 17 (1984).Google Scholar
  12. 12.
    S. Goto, H. Hirano and R. R. Rojas-Corona, Immunohistochemical visualization of afferent nerve terminals in human globus pallidus and its alteration in neostriatal neurodegenerative disorders, Acta Neuropathol. (Berl.). 78: 543 (1989).Google Scholar

Copyright information

© Plenum Press, New York 1990

Authors and Affiliations

  • Sadayuki Matsumoto
    • 1
  • Satoshi Goto
    • 1
  • Hidehiro Mizusawa
    • 1
  • Asao Hirano
    • 1
  1. 1.Bluestone Laboratory of the Division of Neuropathology Department of Pathology, Montefiore Medical CenterAlbert Einstein College of MedicineBronxUSA

Personalised recommendations